These interactions are at the basis of DOT1L involvement in cancer development, as in some types of mixed lineage leukemia in which the fusion between MLL1 protein and DOT1L partners (such as ENL, AF9, or AF10) leads to the ectopic activation of MLL1 target genes by DOT1L11–13. Here, KMT2A is linked to cancer.